Corteria Pharmaceuticals
PrivateLast Round
Series A
Sep 7, 2023
Total Funding Raised
$84.6M
Company Overview
Corteria Pharmaceuticals operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series A round in September 2023.
Corteria Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapies for heart failure, obesity, and related metabolic indications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Corteria Pharmaceuticals Comparables
Compare Corteria Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novo Nordisk | 76% | |
| Bayer AG | 68% | |
| Neurocrine Biosciences | 64% |
For institutional investors. Book with your work email.
Corteria Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 7, 2023 | ||||
| Seed | Dec 9, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Corteria Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fountain Healthcare Partners | Series A, Seed |
| OrbiMed | Series A |
| V-Bio Ventures | Series A, Seed |
| Omnes Capital | Series A, Seed |
| Invivo Partners | Series A, Seed |
| Jeito Capital | Series A |
| Kurma Partners | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 288% MoM, reaching 3.3K.
- Sep 7, 2023
$71M round led by Jeito Capital and OrbiMed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 16, 2026
Corteria Pharma attends EASD 2026 in Italy, where preclinical data on COR-1389 receives an oral presentation.
For institutional investors. Book with your work email.
Corteria Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Corteria Pharmaceuticals's valuation, stock price, and market status.
Is Corteria Pharmaceuticals a public or private company?
Corteria Pharmaceuticals is a private company.
What is the current stock price of Corteria Pharmaceuticals?
Corteria Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Corteria Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Corteria Pharmaceuticals worth (valuation)?
Valuation information for Corteria Pharmaceuticals is not publicly available.
Can I buy Corteria Pharmaceuticals stock?
Corteria Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Corteria Pharmaceuticals's last funding round?
Corteria Pharmaceuticals's most recent funding round was Series A on September 7, 2023.
Who are the main investors in Corteria Pharmaceuticals?
Key investors in Corteria Pharmaceuticals include OrbiMed, Jeito Capital, Kurma Partners.
Will Corteria Pharmaceuticals IPO soon?
No public IPO plans have been announced for Corteria Pharmaceuticals.
How can I track Corteria Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Corteria Pharmaceuticals's shares on secondary markets.